Company news

Shanghai Henlius Biotech, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2026

November 3, 2026

Documents on Display - CONTINUING CONNECTED TRANSACTION - REVISION OF ANNUAL CAP FOR THE COLLABORATION ARRANGEMENTS UNDER THE HLX01 AGREEMENT

November 2, 2026

Proxy form for the 2026 first extraordinary general meeting to be held on Monday, 23 November 2026 (or any adjournment thereof)

November 2, 2026

Notice of extraordinary general meeting

November 2, 2026

(1) Continuing connected transaction revision of annual cap for the collaboration arrangements under the HLX01 agreement (2) proposed appointment of non-executive director and independent non-executive director and notice of extraordinary general meeting

November 2, 2026

Continuing connected transaction - revision of annual cap for the collaboration arrangements under the HLX01 agreement

October 27, 2026

Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026

October 6, 2026

List of directors and their roles and functions

September 30, 2026

(1) Changes in non-executive director and independent non-executive director (2) appointment of chairman of the board and changes in composition of the board committees

September 30, 2026

Interim report 2026

September 24, 2026

Voluntary announcement - collaboration and license agreement with amberstone for two T Cell Engager products

September 23, 2026

Henlius Reports 2026 Interim Results: Sustained Profitability Leap, Advancing Global Value Validation

August 21, 2026

Henlius Reports 2026 Interim Results: Sustained Profitability Leap, Advancing Global Value Validation, and Accelerating Progress Towards C-MNC

August 21, 2026

Henlius and Sandoz Enter Strategic Collaboration to Unlock Global Value of Biosimilars Platform

August 17, 2026

FDA Approves Shanghai Henlius Biotech IND For Cetuximab Biosimilar

May 28, 2026

Henlius Announces IND Approval from NMPA for Its Proprietary c-Met/EGFR Bispecific ADC HLX48

May 22, 2026

European Commission (EC) Approves Henlius and Organon's POHERDY® (pertuzumab), the First Approved Biosimilar to PERJETA (pertuzumab) in Europe

April 29, 2026

NMPA Grants IND Approval for Henlius Nivolumab Biosimilar HLX18 Following U.S. FDA Clearance

March 23, 2026

Henlius Reports 2025 Results: Sustained Growth in Both Revenue and Profit, Advancing Innovation Validation and Global Operations

March 20, 2026

Henlius Obtains Japan MAH License Strengthening Presence in the World's Fourth-Largest Pharmaceutical Market

March 2, 2026

Eisai and Henlius Enter into Exclusive Commercial License Agreement for Anti-PD-1 Antibody Serplulimab in Japan

February 5, 2026

Henlius Showcases "Globalisation 2.0" Strategy and Mid-to-Long-Term Innovation Blueprint at JPM 2026

January 16, 2026

Henlius Fifth U.S. Filing Product Bevacizumab Biosimilar HLX04 Receives FDA BLA Acceptance

January 14, 2026

Henlius CEO Dr. Jason Zhu to Deliver a Keynote Presentation at JPM 2026

December 23, 2025

Henlius' Serplulimab (anti-PD-1 mAb) Granted Breakthrough Therapy Designation by China NMPA for Neo-/Adjuvant Treatment for Gastric Cancer

November 20, 2025

Henlius and Organon Announce US FDA Approval of POHERDY® (pertuzumab-dpzb), the First PERJETA (pertuzumab) Biosimilar in the US

November 17, 2025

Forlong Biotechology Announces Collaboration Agreement with Henlius to Develop Innovative Cancer Immunotherapy with an Engineered Cytokine

October 22, 2025

Phase 3 Clinical Trial of HANSIZHUANG Plus Chemotherapy Meets Primary Endpoint in Neoadjuvant/Adjuvant Gastric Cancer, Greenlighting Early NDA Submission

October 9, 2025

European Commission (EC) Approves Henlius and Organon's BILDYOS® (denosumab) and BILPREVDA® (denosumab), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively

September 19, 2025

FUTUONING Sets Sail Commercially with First Prescriptions Across China

September 5, 2025

US Food and Drug Administration (FDA) Approves Henlius and Organon's BILDYOS® (denosumab-nxxp) and BILPREVDA® (denosumab-nxxp), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively

September 2, 2025

Henlius Keeps Steady Growth in H1 2025: Overseas Product Profits Soar 200%+, Innovation Fuels Global Reach

August 25, 2025

HanchorBio and Henlius Sign Major Licensing Deal for HCB101 to Expand Global Immuno-Oncology Reach

July 1, 2025

Henlius Enters into License Agreement with Sandoz for Proposed Ipilimumab Biosimilar

April 29, 2025

Henlius 2025 Global R&D Day: Harnessing the Power of Innovation to Propel Global Strategy to New Heights

April 17, 2025

Putting Patients First, Co-Creating a Bright Future for Human Health: Henlius Releases 2024 ESG Report

April 16, 2025

Henlius 2024 Annual Results: Steady Revenue Growth with a Net Profit of RMB820.5 million, Up by 50.3% YoY

March 24, 2025

Henlius Receives Orphan Drug Designation for Innovative Anti-HER2 mAb HLX22 in the U.S. for Gastric Cancer

March 19, 2025

FDA Accepts BLA For Shanghai Henlius Biotech's HLX11, A Pertuzumab Biosimilar

February 11, 2025

Henlius and Dr. Reddy's Ink Licensing Deal for HLX15 (investigational daratumumab biosimilar) Expansion in Europe and the U.S.

February 6, 2025

Shanghai Henlius Biotech, Inc. - US FDA Accepts Biologics License Application for HLX11, Biosimilar Candidate of Perjeta

February 3, 2025

Decks

The 5 newest of 18 decks. Every deck is listed under its year.